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Abstract
Recent genome-wide association studies of Alzheimer’s disease (AD) have identified variants in BIN1, CLU, CR1 and PICALM
that show replicable association with risk for disease. We have thoroughly sampled common variation in these genes,
genotyping 355 variants in over 600 individuals for whom measurements of two AD biomarkers, cerebrospinal fluid (CSF) 42
amino acid amyloid beta fragments (Ab42) and tau phosphorylated at threonine 181 (ptau181), have been obtained.
Association analyses were performed to determine whether variants in BIN1, CLU, CR1 or PICALM are associated with
changes in the CSF levels of these biomarkers. Despite adequate power to detect effects as small as a 1.05 fold difference,
we have failed to detect evidence for association between SNPs in these genes and CSF Ab42 or ptau181 levels in our sample.
Our results suggest that these variants do not affect risk via a mechanism that results in a strong additive effect on CSF
levels of Ab42 or ptau181.
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Introduction
Alzheimer’s disease (AD) is the most common form of dementia
and is neuropathologically characterized by extracellular senile
plaques containing amyloid beta (Ab) and intracellular neurofi-
brillary tangles containing hyperphosphorylated tau protein.
Mendelian forms of the disease are caused by mutations in the
amyloid precursor protein (APP) gene and the presenilin 1 and 2
genes (PSEN1 and PSEN2 respectively). While only apolipoprotein
E( APOE) has been clearly identified as a susceptibility gene in the
more common form of AD, data from recent genome-wide
association studies has implicated several other common risk
variants [1,2,3,4,5,6,7,8]. Variants in bridging integrator 1 (BIN1),
clusterin (CLU; also referred to as APOJ), complement component
receptor 1 (CR1) and phosphatidylinositol binding clathrin
assembly protein (PICALM) have already been reported to show
replicable association with risk for AD [5,6,7,8].
Identifying associated variants is an important first step toward
understanding novel aspects of the etiology of disease. Character-
ization of the mechanisms by which these variants, or other
functional variants in strong linkage disequilibrium, influence risk
for disease will provide a better understanding of the biology of
disease. Initial publications for these novel, AD associated variants
providedsome hypotheses foreach ofthereported genes. Previously
reported work suggests that CLU and APOE may have additive
effects on Ab deposition [9]. CR1 may contribute to Ab clearance
[10]. Convincing evidence for an Ab-related mechanism for risk
exists for both of these genes. Less is known about the effects of
BIN1 and PICALM on Ab or tau metabolism: BIN1 function may
affect risk for AD by altering neuronal membranes and clathrin
mediated synaptic vessel formation [8,11] and changes in PICALM
function result in perturbation at the synapse, possibly altering
synaptic vesicle cycling and leading to altered risk for AD [12,13].
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e15918In our previous work we have shown the utility of using two
well-established cerebrospinal fluid (CSF) biomarkers for AD, 42
amino acid fragments of amyloid beta (Ab42; decreased in AD) and
tau phosphorylated at threonine 181 (a proxy for hyperpho-
sphorylated tau; ptau181; increased in AD), as endophenotypes for
genetic studies of AD [14,15,16,17]. In this approach we test
variants for genetic association with CSF levels of Ab42 and/or
ptau181 levels. In cases where risk variants have already been
identified this approach allows us to validate or generate
hypotheses regarding the biological mechanism of risk. We can
also take advantage of the increased statistical power and
decreased heterogeneity of the biomarker phenotype relative to
qualitative clinical diagnosis to identify novel variants that affect
biomarker levels and aspects of disease [18]. In our previous
studies using this approach we have successfully validated
hypothesized effects of rs2986019 in CALHM1 on CSF Ab42
levels [19], generated testable biological hypotheses for AD
implicated variants [16], and identified novel variants in MAPT
and PPP3R1 that are associated with both biomarker levels and
rate of progression of AD [14,17]. In this study we use an
endophenotype-based approach to test predictions of biological
effects on Ab42 levels for variants in CLU and CR1 and to attempt
to generate biological hypotheses of risk mechanism for BIN1,
CLU, CR1 and PICALM.
Methods
Samples
CSF for the Washington University in St. Louis (WU) series was
collected from 407 individuals after overnight fasting. CSF
collection and processing as well as CSF biomarker measurements
were performed as described previously [20]. Characteristics of the
sample, including a breakdown of demographic information in
demented and non-demented individuals can be found in table 1.
Data from 257 samples with biomarker data and either AD or
cognitively normal diagnoses from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) were also used. Data used in
the preparation of this article were obtained from the ADNI
database (www.loni.ucla.edu\ADNI). The Principal Investigator
of this initiative is Michael W. Weiner, M.D., VA Medical Center
and University of California – San Francisco. ADNI is the result of
efforts of many co-investigators from a broad range of academic
institutions and private corporations, and subjects have been
recruited from over 50 sites across the U.S. and Canada. The
initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to
participate in the research — approximately 200 cognitively
normal older individuals to be followed for 3 years, 400 people
with mild cognitive impairment (MCI) to be followed for 3 years,
and 200 people with early AD to be followed for 2 years.’’ For up-
to-date information see www.adni-info.org. Sample characteristics,
including age, clinical dementia rating, gender, APOE e4 status
and mean and standard deviation of the CSF biomarkers can be
found in table 1. ADNI phenotype and GWAS data are publically
available (www.loni.ucla.edu\ADNI). The genotypes from this
study will be provided upon request to the authors.
Biomarker values in both samples were measured using internal
standards and controls that ensure consistent and reliable
measurements. Differences between the measured values in the
WU and ADNI samples are likely to be due to differences in the
antibodies and measurement technologies used for each series (e.g.
standard ELISA with Innotest in the WU samples, Luminex with
AlzBia3 in the ADNI samples). It is also possible that the inclusion
of more AD cases and older individuals in the ADNI data or
differences in the number of freeze thaw cycles prior to analysis (1
cycle for WU samples and 2 cycles for ADNI samples) accounts for
some of the variation in the biomarker measurements. CSF
biomarkers in the two samples show association with similar
covariates [17,19].
SNP selection and genotyping
For each gene we downloaded the list of SNPs in the gene
region (and approximately 500 kb of flanking sequence) from
HapMap. These SNPs were then evaluated for putative functional
effects using SNPseek and Pupasuite. SNPs with putative function
and SNPs that showed association in the original published reports
were designated as forced tags in the tagging algorithm in
Haploview when an r
2 cutoff of 0.8 was applied. A total of 283
SNPs were selected (see table S1 for a list of all SNPs in the study).
Genotyping was performed using Applied Biosystems OpenArr-
ay technology (http://www3.appliedbiosystems.com/cms/groups/
mcb_support/documents/generaldocuments/cms_058198.pdf), a me-
ans of running multiple TaqMan assays together on one chip. 125 ng
per sample was added to the reaction mix and spread over 64 assays,
the chips were thermocycled as described in the linked protocol and
Table 1. Sample characteristics.
WU ADNI
All Cases Controls All Cases Controls
N 407 102 305 257 154 103
age (SD) 69 (10) 74 (8) 67 (11) 76 (7) 75 (8) 77 (5)
CDR 0=71% 0.5=17%
1=5.6% 2=0.4%
All.0 All=0 0=40% 0.5=27%
1=28% 2=3%
All.0A l l = 0
% f e m a l e 6 24 66 75 65 95 0
%e4pos 37 54 34 47 64 23
Ab42 (SD)
1575 (244)
1429 (195)
1621 (240)
2173 (58)
2149 (46)
2208 (55)
ptau181 (SD)
162 (34)
183 (42)
156 (27)
234 (19)
240 (19)
224 (14)
Sample size (N), mean and standard deviation for age in years, Clinical Dementia Ratings (CDR), the percentage of females in the sample (%female), percentage of the
sample that carries at least one APOE e4 allele (%e4pos) and the mean and standard deviation for Ab42 in pg/ml and ptau181 in pg/ml for the complete Washington
University CSF sample (WU: All), cases and controls and the complete Alzheimer’s Disease Neuroimaging Initiative (ADNI: All), cases and controls are shown.
1analyzed with Innotest ELISA (Innogenetics, Ghent, Belgium).
2analyzed with AlzBia3 (xMAP) assay (Innogenetics, Ghent, Belgium).
doi:10.1371/journal.pone.0015918.t001
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software(https://products.appliedbiosystems.com/ab/en/US/adirect/
ab?cmd=catNavigate2&catID=607267&tab=Literature). Samples
were analyzed on a plate-by-plate basis in the context of all the samples
to eliminate variation in calls between plates. SNPs that deviated from
HW equilibrium (p-value threshold 0.001), had a genotyping rate lower
t h a n9 5 %o ram i n o ra l l e l ef r e q u e n cy of less than 5% were removed.
Samples with a genotyping rate lower than 95% were also removed.
After application of these quality control criteria there were 664 samples
and 233 SNPs.
Analysis
Ptau181 levels were normally distributed after log-log transfor-
mation. Using stepwise regression analysis we identified age, APOE
e4 genotype and Clinical Dementia Rating (CDR) as significant
covariates to be included in the model. Gender was not
significantly associated with CSF ptau181, and was not included
in the model. Association with genotype was tested using
ANCOVA after adjustment for these covariates. For the combined
analysis we also included site as a covariate. All analyses were also
performed without CDR as a covariate but there were no
qualitative differences in the results.
Ab42 levels were not normally distributed even after a variety of
transformations were applied. For this reason Ab42 analyses were
performed using permutation based testing in PLINK (1 million
permutations) [21]. For the WU data the statistical analyses
included age, CDR and APOE e4 genotype as covariates; the
ADNI model included CDR and APOE e4 genotype. Age was not
significantly associated with biomarker levels in the ADNI sample
(due to lack of variation in age in the ADNI sample) and was
therefore not included as a covariate for analyses of that sample
alone. Site was included in the combined analysis in addition to
age, CDR and APOE e4 genotype. There were no qualitative
differences in the results when run without CDR as a covariate.
The alpha level for this study using Bonferroni correction for
233 tests is 0.00021. A less conservative correction using the Eigen
values of the SNP correlation matrix to estimate the effective
number of tests yielded an adjusted alpha of 0.00022 [22,23].
Using either adjusted alpha yields the same qualitative conclusions
from these data.
Haplotype and set-based analyses were performed using PLINK
with default settings [21]. The SNPs selected for fine mapping
around each GWAS hit were defined as a set and 10,000
permutations were run using the same models as described
previously for each phenotype.
Power
Power for the overall F test in a one-way, three-group analysis of
variance was calculated using proc power in SAS. The effect size,
measured in ‘‘fold-difference’’ between the means at which power
was estimated at 0.80 was calculated for minor allele frequencies
from 0.10 to 0.50 and alpha levels of 0.05 and 0.00021 (the
Bonferroni correction for 233 tests) assuming markers do not
deviate from Hardy-Weinberg Equilibrium (table 2).
Results
We failed to detect significant association between the CSF
biomarker levels and SNPs in BIN1. rs3820757 (p=0.31),
rs744373 (p=0.44) and rs2276582 (p=0.48) had the smallest
p-value for association with CSF Ab42 levels but did not show
statistically significant association in the combined sample
(WU+ADNI CSF samples, table 3). The three top hits in BIN1
for CSF ptau181 did not show statistically significant association
(table 4). The SNP identified in previous GWAS, rs744373, did
not show an association with CSF ptau181 levels in the combined
sample (p=0.79; table 4). Set-based analyses of the 14 BIN1 fine
mapping SNPs were not significant for either biomarker
phenotype (Ab42 p=0.42; ptau181 p=0.37). Haplotype analyses
also failed to identify significant association with Ab42 and ptau181.
We failed to detect evidence for association between rs11136000
in CLU, which has been implicated in risk for AD, and CSF Ab42
(p=0.79) or ptau181 (p=0.78) levels (Tables 3 and 4) in the
combined sample. The top hits for CSF Ab42 levels in CLU were
rs10216623 (p=0.011), rs2640734 (p=0.036) and rs17057419
Table 2. Power analyses.
Minor allele
frequency Effect size when power=0.80
alpha=0.05 alpha=0.00021
0.1 1.03 1.05
0.15 1.026 1.042
0.2 1.024 1.038
0.25 1.022 1.035
0.3 1.02 1.033
0.35 1.019 1.032
0.4 1.019 1.03
0.45 1.019 1.03
0.5 1.019 1.03
Power to detect genetic association. Power for the overall F test in a one-way,
three group analysis of variance. The effect size, measured in ‘‘fold-difference’’
between the means at which power was estimated at 0.80 was calculated for
minor allele frequencies from 0.10 to 0.50 and alpha levels of 0.05 and 0.00021.
doi:10.1371/journal.pone.0015918.t002
Table 3. Top hits and GWAS SNPs for CSF Ab42.
SNP Gene WU ADNI Combined
rs3820757 BIN1 0.14 0.43 0.31
rs744373* BIN1 0.45 0.32 0.44
rs2276582 BIN1 0.27 0.43 0.48
rs10216623 CLU 0.0011 0.81 0.011
rs2640734 CLU 0.05 0.07 0.036
rs17057419 CLU 0.09 0.38 0.056
rs11136000* CLU 0.92 0.14 0.79
rs1048971 CR1 0.47 0.80 0.25
rs17258996 CR1 0.38 0.96 0.32
rs2296160 CR1 0.32 0.75 0.33
rs6656401* CR1 0.55 0.72 0.63
rs7113656 PICALM 0.053 0.69 0.0090
rs11234454 PICALM 0.0088 0.34 0.01
rs10792828 PICALM 0.0074 0.021 0.011
rs3851179* PICALM 0.64 0.52 1.0
Association with CSF Ab42 levels. P-values for association between the top three
hits and CSF Ab42 levels in the Washington University (WU), Alzheimer’s Disease
Neuroimaging Initiative (ADNI) and Combined series.
*SNPs that are significant in previously reported genome-wide association
studies are also shown, even when not ranked in the top three hits.
doi:10.1371/journal.pone.0015918.t003
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The top hits in CLU for association with CSF ptau181 were
rs2439497 (p=0.0010), rs2640734 (p=0.004) and rs576256
(p=0.0081) in the combined sample. The p-value threshold for
Bonferroni correction for the entire study is 0.00021; therefore
none of these p-values pass the multiple test correction. Set-based
analyses of 57 SNPs from the CLU fine mapping set showed that
there was evidence for association with ptau181 levels (p=0.034).
However this p-value is not significant after correction for the 4
SNP sets that were tested. There was no evidence for association in
the set-based analyses for Ab42 levels (p=1). Haplotype analyses
failed to identify significant association with either CSF phenotype.
The SNP in CR1 that is implicated in risk for disease from
recent GWAS is rs6656401. We failed to detect association
between this SNP and either CSF Ab42 (p=0.63) or ptau181
(p=0.52) levels in the combined sample. In CR1 no SNPs were
significant with either phenotype (table 3 and 4) and set-based
analyses of the 24 SNPs within the CR1 fine-mapping region
provided no evidence for association (Ab42 p=1; ptau181 p=1).
Haplotype analyses failed to detect significant association with
Ab42 and ptau181.
Rs3851179, the PICALM SNP identified in the recent GWAS
studies showed no evidence of association with either CSF Ab42 or
ptau181 levels (Tables 3 and 4). The top hits for CSF Ab42 levels
were rs7113656 (p=0.0090), rs11234454 (p=0.010) and
rs10792828 (p=0.011). The top hits for CSF ptau181 levels were
rs638509 (p=0.00098), rs694353 (p=0.0010) and rs10898433
(p=0.0012). Set-based analyses of 138 SNPs in the PICALM fine-
mapping region failed to detect evidence for association with either
Ab42 (p=0.56) or ptau181 (p=0.47). Haplotype analyses also failed
to identify significant association with these CSF phenotypes.
There is evidence of an interaction between SNPs in PICALM
and APOE e4, in at least one study the effects of risk associated
SNPs in PICALM were found to be much stronger in the presence
of the APOE e4 allele [6]. To investigate this interaction we
included an interaction term for PICALM SNPs and the presence
or absence of APOE e4 and performed association analyses
between PICALM SNP genotypes and CSF Ab42 and ptau181 in
APOE e4 positive and APOE e4 negative substrata and using an
APOE e4 by SNP interaction term in the combined sample. We
failed to detect statistically significant associations in the APOE e4
negative and APOE e4 positive substrata and in the interaction
analysis (table S2). The most significant p-value from these three
analyses is for association of rs11234542 with CSF ptau181 levels in
the APOE e4 negative substratum (p=5.31610
-5; table S2). In this
case the minor allele of rs11234542 was associated with higher
CSF ptau181 levels.
Power to detect additive effects of more than an approximately
1.02 fold difference between the means was greater than 0.80
when alpha is 0.05 for all SNPs in this study. Even with an
extremely conservative alpha of 0.00021 (Bonferroni correction for
233 tests) all SNPs in this study had power estimated at greater
than 0.80 for at least a 1.05 fold difference (for reference significant
association detected between rs2986019 in CALHM1 on CSF Ab42
levels by Kauwe et al was a 1.05 fold difference [19]).
Discussion
While there were some suggestive associations of CSF ptau181
levels with PICALM SNPs, we failed to detect association that was
significant after multiple test correction between SNPs in BIN1,
CLU, CR1 or PICALM and CSF Ab42 or ptau181 levels in our
analyses. The power calculations suggest that our single snp tests
had a very high probability of detecting a strong, additive effect
(1.05 fold difference) on CSF biomarker levels if it were present.
The lack of significant associations suggests that there is not likely
to be a strong additive genetic effect between the SNPs in this
study and CSF levels of Ab42 or ptau181. A recently published
GWAS of 17 plasma lipoproteins in a sample of over 17,000
individuals identified 43 associated loci [24]. Close review of the
results of that study shows that approximately one third of the
significant associations show less than a 1.05-fold difference and
about one sixth show less than a 1.03-fold difference. These
findings suggest that small additive effects on protein levels are
common and that much larger numbers of CSF samples will be
required to precisely determine associations between Alzheimer’s
disease risk variants and biomarker levels. Greater sample sizes,
while not immediately available, will be possible as we and other
groups continue to collect additional specimens. Our set-based
analyses suggest that there may be a signal for association with
CSF ptau181 in the CLU gene region. This result, and the lack of
signal with Ab levels, are unexpected given data suggesting
additive effects of CLU and APOE on Ab deposition in mice [9].
The association is not significant after correction for the four sets
that were tested but suggests that with increased power significant
biomarker association may be detected.
An alternative interpretation of our results is that, given the lack
of association with Ab42 and ptau181, variants in these genes may
modulate risk for AD through mechanisms that do not directly
alter CSF levels of Ab42 or ptau181. CLU, PICALM and CR1
participate in other processes not related to Ab or tau aggregation,
processing or clearance, and therefore studies of the role of these
proteins in the brain may reveal evidence for additional disease
mechanisms, which go beyond Ab or tau accumulation. In fact
there are several studies that link these genes with lipid metabolism
and inflammatory pathways. Two of the identified AD suscepti-
bility genes (CLU, CR1) have known functions in the immune
system, which suggests a possible role for the immune system in the
Table 4. Top hits and GWAS SNPs for ptau181.
SNP Gene WU ADNI Combined
rs9653202 BIN1 0.019 0.82 0.077
rs1060743 BIN1 0.46 0.075 0.093
rs6431221 BIN1 0.059 0.74 0.10
rs744373* BIN1 0.77 0.80 0.79
rs2439497 CLU 0.02 0.02 0.0010
rs2640734 CLU 0.05 0.05 0.0040
rs576256 CLU 0.12 0.04 0.0081
rs11136000* CLU 0.33 0.66 0.78
rs2274567 CR1 0.76 0.12 0.18
rs9429940 CR1 0.15 0.89 0.20
rs17616 CR1 0.84 0.19 0.28
rs6656401* CR1 0.75 0.39 0.52
rs638509 PICALM 0.0022 0.10 0.00098
rs694353 PICALM 0.00043 0.34 0.0010
rs10898433 PICALM 0.019 0.022 0.0012
rs3851179* PICALM 0.74 0.61 0.54
Association with CSF ptau181 levels. P-values for association between the top
three hits and CSF ptau181 levels in the Washington University (WU), Alzheimer’s
Disease Neuroimaging Initiative (ADNI) and Combined series.
*SNPs that are significant in previously reported genome-wide association
studies are also shown, even when not ranked in the top three hits.
doi:10.1371/journal.pone.0015918.t004
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and lipid metabolism have also been identified and are reviewed
by Jones et al [27].
Our study was designed specifically to detect additive genetic
effects of common SNPs. Failure to detect significant association in
this study design does not rule out, or even directly address, the
possibility that these genes harbor rare variation that influence
these biomarkers or that common variants in these genes have
very small effects on these biomarkers. Finally, this approach may
not detect complex, non-additive genetic mechanisms, such as
complex gene-gene or gene-environment interactions that may
modulate biomarker levels.
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Table S1 A complete list of SNPs in the study, position,
minor allele frequencies (MAF), and p-values for
association with CSF ptau181 and Ab42 levels in the
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for association with CSF ptau181 and Ab42 levels for the SNP by
presence/absence of the APOE e4 allele interaction term,
association in individuals without an APOE e4 allele and
association in individuals with an APOE e4 allele are shown.
(DOCX)
Acknowledgments
We thank contributors, including the Alzheimer’s Disease Centers who
collected samples used in this study, as well as patients and their families,
whose help and participation made this work possible. The authors also
acknowledge the contributions of the Genetics, Clinical, Psychometric,
Biomarker and Biostatistics Cores of the Washington University Alzhei-
mer’s Disease Research Center.
Some of the data used in the preparation of this article were obtained
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(www.loni.ucla.edu\ADNI). As such, the investigators within the ADNI
contributed to the design and implementation of ADNI and/or provided
data but did not participate in analysis or writing of this report. ADNI
investigators include (complete listing available at http://www.loni.ucla.
edu/ADNI/About/About_Investigators.shtml).
Author Contributions
Conceived and designed the experiments: AMG JSKK CC. Performed the
experiments: CC CMK BS KM. Analyzed the data: JSKK CC CMK BS
ML WL MS. Contributed reagents/materials/analysis tools: DMH AMF
JCM ADNI. Wrote the paper: JSKK CC AMG ML KM WL CMK.
References
1. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, et al. (2009) Genome-
wide association study implicates a chromosome 12 risk locus for late-onset
Alzheimer disease. Am J Hum Genet 84: 35–43.
2. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, et al. (2008) Genome-
wide association analysis reveals putative Alzheimer’s disease susceptibility loci in
addition to APOE. Am J Hum Genet 83: 623–632.
3. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, et al. (2009) Genetic
variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s
disease. Nat Genet 41: 192–198.
4. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, et al. (2007) A high-
density whole-genome association study reveals that APOE is the major
susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry
68: 613–618.
5. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009)
Genome-wide association study identifies variants at CLU and PICALM
associated with Alzheimer’s disease. Nat Genet 41: 1088–1093.
6. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, et al. (2010) Meta-analysis
Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and
Reveals Interactions With APOE Genotypes. Arch Neurol.
7. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-
wide association study identifies variants at CLU and CR1 associated with
Alzheimer’s disease. Nat Genet 41: 1094–1099.
8. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. (2010)
Genome-wide analysis of genetic loci associated with Alzheimer disease. Jama
303: 1832–1840.
9. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O’Dell MA, et al. (2004)
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence
that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41:
193–202.
10. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, et al. (2002)
Prominent neurodegeneration and increased plaque formation in complement-
inhibited Alzheimer’s mice. Proc Natl Acad Sci U S A 99: 10837–10842.
11. Wigge P, Kohler K, Vallis Y, Doyle CA, Owen D, et al. (1997) Amphiphysin
heterodimers: potential role in clathrin-mediated endocytosis. Mol Biol Cell 8:
2003–2015.
12. Harel A, Wu F, Mattson MP, Morris CM, Yao PJ (2008) Evidence for CALM in
directing VAMP2 trafficking. Traffic 9: 417–429.
13. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, et al. (2001) Altered
expression of synaptic proteins occurs early during progression of Alzheimer’s
disease. Neurology 56: 127–129.
14. Kauwe JS, Cruchaga C, Mayo K, Fenoglio C, Bertelsen S, et al. (2008)
Variation in MAPT is associated with cerebrospinal fluid tau levels in the
presence of amyloid-beta deposition. Proc Natl Acad Sci U S A 105: 8050–8054.
15. Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, et al. (2007) Extreme
cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer’s
disease presenilin 1 mutation. Ann Neurol 61: 446–453.
16. Kauwe JS, Wang J, Mayo K, Morris JC, Fagan AM, et al. (2009) Alzheimer’s
disease risk variants show association with cerebrospinal fluid amyloid beta.
Neurogenetics 10: 13–17.
17. Cruchaga C, Kauwe JSK, Mayo K, Spiegel N, Bertelsen S, et al. (2010) SNPs
Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of
Decline in Alzheimer’s Disease. PLoS Genet 6: e1001101.
18. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and
‘‘preclinical’’ Alzheimer’s disease. Ann Neurol 45: 358–368.
19. Kauwe JS, Cruchaga C, Bertelsen S, Mayo K, Latu W, et al. (2010) Validating
Predicted Biological Effects of Alzheimer’s Disease Associated SNPs Using CSF
Biomarker Levels. J Alzheimers Dis.
20. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, et al. (2006) Inverse
relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42
in humans. Ann Neurol 59: 512–519.
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
22. Cheverud JM (2001) A simple correction for multiple comparisons in interval
mapping genome scans. Heredity 87: 52–58.
23. Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the
eigenvalues of a correlation matrix. Heredity 95: 221–227.
24. Chasman DI, Pare G, Mora S, Hopewell JC, Peloso G, et al. (2009) Forty-three
loci associated with plasma lipoprotein size, concentration, and cholesterol
content in genome-wide analysis. PLoS Genet 5: e1000730.
25. McLaughlin L, Zhu G, Mistry M, Ley-Ebert C, Stuart WD, et al. (2000)
Apolipoprotein J/clusterin limits the severity of murine autoimmune myocar-
ditis. J Clin Invest 106: 1105–1113.
26. Jozsi M, Prechl J, Bajtay Z, Erdei A (2002) Complement receptor type 1 (CD35)
mediates inhibitory signals in human B lymphocytes. J Immunol 168:
2782–2788.
27. Jones L, Harold D, Williams J (2010) Genetic evidence for the involvement of
lipid metabolism in Alzheimer’s disease. Biochim Biophys Acta 1801: 754–761.
Association of AD Risk Genes with CSF Biomarkers
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e15918